SILO WELLNESS INC.
Silo Wellness Inc., a psychedelics and wellness company, develops psychedelic medicine to reduce trauma. The company develops and sells psilocybin-free functional mushroom tinctures; and the formulation of a psilocybin nasal spray in Jamaica. It also offers a portfolio of functional mushroom products: Jamaican and Oregon psychedelic wellness retreats. The company was formerly known as Yukoterre R… Read more
SILO WELLNESS INC. (3K7A) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SILO WELLNESS INC. (3K7A) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SILO WELLNESS INC. - Net Assets Trend (None–None)
This chart illustrates how SILO WELLNESS INC.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SILO WELLNESS INC. (None–None)
The table below shows the annual net assets of SILO WELLNESS INC. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SILO WELLNESS INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SILO WELLNESS INC. Competitors by Market Cap
The table below lists competitors of SILO WELLNESS INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ligand Pharms Inc Cvr
PINK:LGNDZ
|
$57.77K |
|
JOH. FRIEDR BEHRENS
HM:JFB
|
$57.80K |
|
YAMAHA CORP - Dusseldorf Stock Exchang
DU:YHA
|
$57.86K |
|
Asia Paper Manufacturing Co. Ltd.
KQ:002310
|
$57.86K |
|
Kardan NV
TA:KRNV
|
$57.69K |
|
Shandong Senter Electn Co Ltd
SHE:001388
|
$57.68K |
|
Advanced Medical Solutions Group plc
LSE:AMS
|
$57.66K |
|
EASYJET
BE:EJT1
|
$57.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SILO WELLNESS INC.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SILO WELLNESS INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SILO WELLNESS INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SILO WELLNESS INC.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SILO WELLNESS INC. (3K7A) | €- | N/A | N/A | $57.71K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |